 |
|
|
Font Size:
|
||||
|
|
|
||||
|
MEPS HC 255: 2024 Medical ConditionsAugust 2026 Agency for Healthcare Research and Quality
A. Data Use Agreement Appendices
1 Variable-Source Crosswalk A. Data Use AgreementIndividual identifiers have been removed from the microdata contained in these files. Nevertheless, under Sections 308 (d) and 903 (c) of the Public Health Service Act (42 U.S.C. § 242m and 42 U.S.C. § 299a-1), data collected by the Agency for Healthcare Research and Quality (AHRQ) and/or the National Center for Health Statistics (NCHS) may not be used for any purpose other than the purpose for which they were supplied; any effort to determine the identity of any reported cases is prohibited by law. Therefore, in accordance with the previously referenced federal statute, it is understood that
By using these data, you signify your agreement to comply with the previously stated statutorily based requirements with the knowledge that deliberately making a false statement in any matter within the jurisdiction of any department or agency of the federal government violates Title 18, Part 1, Chapter 47, Section 1001 (18 U.S.C. § 1001), and is punishable by a fine of up to $10,000 or up to 5 years in prison. AHRQ requests that users cite AHRQ and the Medical Expenditure Panel Survey as the data source in any publications or research based on these data. B. Background1.0 Household ComponentThe Medical Expenditure Panel Survey (MEPS) provides nationally representative estimates of healthcare use, expenditures, payment sources, and health insurance coverage for the U.S. civilian noninstitutionalized population. The MEPS Household Component (HC) also provides estimates of respondents’ health status, demographic and socio-economic characteristics, employment, access to care, and satisfaction with care. Estimates can be produced for individuals, families, and selected population subgroups. The survey’s panel design includes five rounds of interviews spanning 2 full calendar years. The interviews use computer-assisted personal interviewing (CAPI) technology or computer-assisted video interviewing (CAVI) technology to collect information about each household member, which the survey builds on from interview to interview. A single household respondent reports all data for a sampled household. The MEPS HC was initiated in 1996. Each year, a new panel of sampled households is selected. Because the data collected are comparable to those from earlier medical expenditure surveys conducted in 1977 and 1987, it is possible to analyze long-term trends. Historically, each annual MEPS HC sample consists of up to 15,000 households. Data can be analyzed at the person, family, or event level. Data must be weighted to produce national estimates. The set of households selected for each MEPS HC panel is a subsample of households participating in the previous year’s National Health Interview Survey (NHIS) conducted by NCHS. The NHIS sampling frame provides a nationally representative sample of the U.S. civilian noninstitutionalized population. In 2006, NCHS implemented a new NHIS sample design that included households with Asian persons in addition to households with Black and Hispanic persons in minority group oversampling. In 2016, NCHS introduced another sample design that discontinued the oversampling of these minority groups. 2.0 Medical Provider ComponentWhen the household CAPI instrument is completed and permission is obtained from the sampled members to contact their medical provider(s), a sample of these providers is contacted by telephone to obtain information that household respondents cannot accurately provide. This part of MEPS is called the Medical Provider Component (MPC), and it collects information on dates of visits, diagnosis and procedure codes, and charges and payments. The Pharmacy Component (PC), a subcomponent of the MPC, does not collect data on charges or on diagnosis and procedure codes, but it does collect detailed information on drugs, including the National Drug Code (NDC) and medicine name, as well as payment amounts. The MPC is not designed to yield national estimates; it is primarily used as an imputation source to supplement or replace household-reported expenditure information. 3.0 Survey Management and Data CollectionMEPS HC and MPC data are collected under the authority of the Public Health Service Act. The MEPS HC data are collected under contract with Westat, and the MEPS MPC data are collected under contract with RTI International. Datasets and summary statistics are edited and published in accordance with the confidentiality provisions of the Public Health Service Act and the Privacy Act. NCHS provides consultation and technical assistance. As soon as the MEPS data are collected and edited, they are released to the public in stages of microdata files and tables via the MEPS website and AHRQ Data Tools site. Additional information on MEPS is available from the MEPS project manager or the MEPS public use data manager at the Center for Financing, Access, and Cost Trends, AHRQ, 5600 Fishers Lane, Rockville, MD 20857. C. Technical and Programming Information1.0 General InformationThis documentation describes the Medical Conditions Public Use File HC 255 (hereafter referred to as the Conditions PUF), which is one in a series of public use data files to be released from the 2024 MEPS HC. It was released as an ASCII file (with related SAS, SPSS, R, and Stata programming statements and data user information), SAS dataset, SAS transport file, Stata dataset, and Excel file. The Conditions PUF provides information on household-reported medical conditions collected from a nationally representative sample of the U.S. civilian noninstitutionalized population for calendar year 2024. It contains 29 variables and has a logical record length of 117 with an additional 2-byte carriage return/line feed at the end of each record. This documentation offers an overview of the types and levels of data provided as well as a detailed description of the content and structure of the files. It is organized into the following sections:
A codebook of all the variables included on the 2024 Conditions PUF is provided in an accompanying file. For more information on the MEPS sample design, see Chowdhury et al. (2019). A copy of the survey instrument used to collect the information in this PUF is available in the Survey Questionnaires section of the MEPS website. 2.0 Data File InformationThe 2024 Conditions PUF contains 67,705 records. Each record represents one current medical condition reported for a household survey member who resides in an eligible responding household and who has a positive person or family weight. A condition is defined as current if it is linked to an event during 2024. Conditions in the Priority Condition Enumeration (PE) section are asked in the context of “has (person) ever been told by a doctor or other health care professional that they have (condition)?” except joint pain and chronic bronchitis, which asks only about the last 12 months. Persons with a response of Yes (1) to a priority condition question for whom the condition is not current as defined above will not have a record for that condition in this PUF. This PUF consists of MEPS survey data obtained in Rounds 3, 4, and 5 of Panel 28, and Rounds 1, 2, and 3 of Panel 29, the rounds for the MEPS panels covering calendar year 2024. Person-level data (e.g., demographic or health insurance characteristics) from the 2024 MEPS Full Year Consolidated PUF (HC 256) can be merged to the records in this file using DUPERSID. Since each record represents a single condition reported by a household respondent, some household members may have multiple medical conditions and thus will be represented by multiple records on this file. Other household members may have no reported medical conditions and thus will have no records on this file. Still other household members may have a reported medical condition that did not meet the criteria above and thus will have no records on this file. Data from this file also can be merged to 2024 MEPS Event Files (HC 254A, and HC 254D through HC 254H) by using the link files provided in HC 254I. (See HC 254I documentation for details.) 2.1 Codebook StructureFor most variables on the Conditions PUF, both weighted and unweighted frequencies are provided in the accompanying codebook file. The exceptions to this are weight variables and variance estimation variables. Only unweighted frequencies of these variables are included on the accompanying codebook file. See the Weights Variables list in Appendix 1: Variable-Source Crosswalk. The codebook and data file list variables in the following order:
The person identifier is unique within this data year. 2.2 Reserved CodesThis Conditions PUF contains several reserved code values (Table 1).
The value Cannot be Computed (-15) was assigned to the MEPS constructed variables when there was not enough information from the instrument to calculate the constructed variables. Not enough information is often the result of skip patterns in the data or of missing information stemming from the responses Refused (-7) or Don’t Know (-8). Note that, in addition to Don’t Know, reserved code -8 also includes cases for which the information from the question was Not Ascertained. 2.3 Codebook FormatThis codebook describes an ASCII dataset (although the data are also provided in an Excel file, Stata dataset, SAS dataset, and SAS transport file) and provides the programming identifiers for each variable (see Table 2).
2.4 Variable Source and Naming ConventionsIn general, variable names reflect the variable’s content. Edited variables end with “X” and are so noted in the variable label. (CONDIDX, which is an encrypted identifier variable, also ends with “X”.) As the collection, universe, or categories of variables were altered, some variable names have been appended with “_Myy”, where “yy” indicates the collection year in which the alterations were made. Such alterations are described in detail throughout this document. Variables in this Conditions PUF were derived either from the questionnaire itself or from the CAPI. The source of each variable is identified in Appendix 1. Sources for each variable are indicated in one of three ways:
2.5 File Contents2.5.1 Identifier Variables (DUID-CONDRN)The definitions of dwelling units (DUs) in the MEPS HC are generally consistent with those used in NHIS. The dwelling unit identifier (DUID) is a seven-digit ID number consisting of a two-digit panel number followed by a five-digit random number assigned after the case was sampled for MEPS. A three-digit person number (PID) uniquely identifies each person within the DU. The variable DUPERSID is the combination of the variables DUID and PID. Identifiers begin with the two-digit panel number. CONDN is the condition number and uniquely identifies each condition reported for an individual. A three-digit CONDN beginning with “9” reflects a condition that was added during the editing process. Note that conditions are not added every year during editing. The range in this PUF for CONDN is 1-60. The variable CONDIDX uniquely identifies each condition (i.e., each record in this PUF) and is the combination of DUPERSID and CONDN. CONDIDX has a length of 13 with DUPERSID (10) and CONDN (3) combined. PANEL is a constructed variable used to specify the panel number and indicates Panel 28 or Panel 29 for each record on this PUF. The panel number is included as the first two digits of the DUID and DUPERSID. CONDRN indicates the round in which the condition was first reported. For a small number of cases, conditions that began in an earlier round were not reported by respondents until subsequent rounds of data collection. During file construction, editing was performed for these cases to reconcile the round in which a condition began and the round in which the condition was first reported. 2.5.2 Medical Condition Variables (AGEDIAG-ICD10CDX)This PUF contains variables describing medical conditions reported by respondents in several sections of the MEPS questionnaire, including sections that collect information about health provider visits, prescription medications, or both (see Variable-Source Crosswalk in Appendix 1 for details). Priority Conditions and Injuries Certain conditions were a priori designated as “priority conditions” due to their prevalence, expense, or relevance to policy. Some of these are long-term, life-threatening conditions, such as cancer, diabetes, emphysema, high cholesterol, hypertension, ischemic heart disease, and stroke. Others are chronic, manageable conditions, including arthritis and asthma. The only mental health condition on the priority conditions list is attention deficit hyperactivity disorder/attention deficit disorder. When a condition was first mentioned, respondents were asked whether it was due to an accident or injury (INJURY=1). Only non-priority conditions (i.e., conditions reported in a section other than PE) are eligible to be injuries. The interviewer is prevented from selecting priority conditions as injuries. Complete List of Conditions Asked in Priority Conditions Enumeration Section:
Age Priority Condition Began The age of diagnosis (AGEDIAG) was collected for all priority conditions, except joint pain. For confidentiality reasons, AGEDIAG is set to Inapplicable (-1) for cancer conditions. To ensure confidentiality, AGEDIAG was top-coded to 85. This corresponds with the age top-coding in person-level PUFs. Follow-up Questions for Injuries When a respondent reported that a condition resulted from an accident or injury (INJURY=1), the respondent was asked whether the accident/injury occurred at work (ACCDNWRK). This question was not asked about persons aged 15 and younger; the condition had ACCDNWRK coded to inapplicable (-1) for those persons. Sources for Conditions on the MEPS Conditions File The records on this PUF correspond with medical condition records collected by CAPI and stored on a person’s MEPS conditions roster. Conditions can be added to the MEPS conditions roster in multiple ways. (1) A condition can be reported in the Priority Condition Enumeration (PE) section in which persons are asked if they have been diagnosed with specific conditions. Conditions reported in the PE section that are not currently included on this PUF. (2) The condition can be identified as the reason reported by the household respondent for a particular medical event (e.g., hospital stay, outpatient visit, emergency room visit, home health episode, prescribed medication purchase, office-based medical provider visit). (3) Some condition information is collected in the MEPS MPC. However, since the MPC is not available for everyone in the sample, it is not used to supplement, replace, or verify household-reported condition data. Treatment of Data from Rounds Not Occurring in 2024 Beginning in 2008, priority conditions are included on the PUF only if they are also current conditions. From 2008-2017, a current condition was defined as a condition linked to an event or a condition the person was currently experiencing (i.e., a condition selected in the Condition Enumeration [CE] section). However, starting in Panel 21 Round 5 and Panel 22 Round 3, a current condition is defined only as a condition linked to a current year event. Conditions from Panel 28 Rounds 1-3 that are not included in the 2024 PUF may be available in the 2023 Conditions PUF if the person had a positive person or family weight in 2023. Note: Priority conditions are generally chronic conditions. Even though a person may not have reported an event in 2024 due to the condition, analysts should consider that the person may still be experiencing the condition. If a Panel 28 person reported a priority condition in Round 1 or 2 and did not have an event for the condition in Round 3, 4, or 5, the condition will not be included on the 2024 Medical Conditions PUF. Rounds in Which Conditions Were Reported/Selected (CRND1 - CRND5) A set of constructed variables indicates the round in which the condition was first reported (CONDRN), and the subsequent round(s) in which the condition was selected (CRND1 - CRND5). The condition may be reported or selected when the person reports an event that occurred due to the condition. For example, consider a condition for which CRND1 = 0, CRND2 = 1, and CRND3 = 1. For non-priority conditions (conditions not asked in the PE section), this sequence of indicators implies that the condition was not present during Round 1 (CRND1 = 0), was first mentioned during Round 2 (CRND2 = 1, CONDRN = 2), and was selected again during Round 3 (CRND3 = 1). For priority conditions, this sequence of indicators implies that the condition was reported in the PE section in Round 1 (CONDRN = 1, CRND1 = 0) but was not connected with an event until Rounds 2 and 3 (CRND2 = 1, CRND3 = 1). Because priority conditions are asked in the context of “has (person) ever been told by a doctor or other health care professional that they have (condition)?” except joint pain and chronic bronchitis, which ask only about the last 12 months, a priority condition might not be selected in the round in which it was first reported. A condition is current if it is linked to an event that occurred in 2024. Diagnosis Codes Medical conditions reported by the HC respondent were recorded by the interviewer using a condition picklist with ICD-10-CM codes already assigned to conditions in the list. Reported conditions not in the picklist were recorded as verbatim text and then were coded to ICD-10-CM codes (ICD10CDX) by professional coders. Coders followed specific guidelines in coding missing values to the ICD-10-CM diagnosis condition variable when a verbatim text string could not be matched to an ICD-10-CM code through the picklist. ICD10CDX was coded -15 (Cannot be Computed) where the verbatim text fell into one of three categories: (1) the text indicated that the condition was unknown (e.g., DK); (2) the text indicated the condition could not be diagnosed by a doctor (e.g., doctor doesn’t know); or (3) the specified condition was not codable. If the text indicated a procedure and the condition associated with the procedure could be discerned from the text, the condition itself was coded. For example, “cataract surgery” would be coded as the condition “other cataract” (ICD10CDX is set to code “H26”). If the condition could not be discerned (e.g., “outpatient surgery”), ICD10CDX was set to -15. To preserve confidentiality, all conditions provided on this PUF have been collapsed to three-digit diagnosis code categories rather than the fully-specified ICD-10-CM code. For example, the ICD10CDX value of J02 “Acute pharyngitis” includes the fully-specified subclassifications J020 through J029; the value F31 “Bipolar disorder” includes the fully-specified subclassifications F3110 through F319. Table 1 in Appendix 2 provides unweighted and weighted frequencies for all ICD-10-CM condition code values reported on the PUF. Less than 1 percent of the ICD-10-CM codes on this PUF were edited further by collapsing two or more three-digit codes into one 3-digit code. This includes clinically rare conditions that were recoded to broader codes by clinicians. A condition is determined to be clinically rare if it appears on the National Institutes of Health’s list of rare diseases. For confidentiality purposes, approximately 10.8% of ICD-10-CM codes were recoded to -15 (Cannot be Computed) for conditions where the frequency was fewer than 40 for the total unweighted population on the PUF or fewer than 400,000 for the weighted population. Additional factors used to determine recoding include age and sex. In a small number of cases, diagnosis and condition codes were recoded to Cannot be Computed (-15) if they denoted a pregnancy for a person younger than 18 or older than 44. Less than one-tenth of 1 percent of records were recoded in this manner on the 2024 Conditions PUF. If the person’s age is under 18 or over 44 in the round in which the pregnancy-related condition was reported, the pregnancy-related condition code was recoded to Cannot be Computed (-15). Users should note that because of the design of the survey, most deliveries (i.e., births) are coded as pregnancies. For more accurate estimates for deliveries, analysts should use RSNINHOS “Reason Entered Hospital” found on the Hospital Inpatient Stays PUF (HC 254D). Conditions PUF data can be merged with the 2024 Event PUFs using the 2024 Condition-Event Link PUF (HC 254I). Because the conditions have been collapsed to three-digit diagnosis code categories rather than the fully-specified ICD-10-CM code, it is possible for there to be duplicate ICD-10-CM condition codes linked to a single medical event when different fully-specified conditions are collapsed to the same three-digit code. Conditions were reported in several sections of the HC questionnaire (see Variable-Source Crosswalk in Appendix 1). Labels for all values of ICD10CDX, as shown in Table 1 of Appendix 2, are provided in the SAS programming statements included in this release (see the H255SU.TXT file). Clinical Classification Software Refined Clinical Classification Software Refined (CCSR) codes are used alongside ICD-10-CM diagnosis codes to group medical conditions into clinically meaningful categories. Although ICD-10-CM diagnosis codes can map to multiple CCSR codes, for the purposes of this PUF, one ICD-10-CM diagnosis code may map to up to four CCSR categories (CCSR1X, CCSR2X, CCSR3X, and CCSR4X) using the v2025.1 release of the CCSR for ICD-10-CM diagnoses. The CCSR codes on this PUF are listed in alphabetical order and do not indicate a primary and secondary diagnosis. For more information on CCSR, visit the user guide for CCSR. For confidentiality purposes, approximately 7.5% of the CCSR categories were collapsed into a broader code for the appropriate body system where the frequency was fewer than 40 for the total unweighted population on the file or fewer than 400,000 for the weighted population. For example, BLD001 (Nutritional Anemia), may be recoded to BLD000 (Disease of Blood and Disorders Involving Immune Mechanism), thus revealing only the body system. Less than one-tenth of 1% of CCSR codes were recoded to Cannot be Computed (-15) based on frequencies of ICD10CDX and CCSR pairs. Table 2 in Appendix 2 provides unweighted and weighted frequencies for CCSR combinations reported on this PUF. 2.5.3 Utilization Variables (OBCOND - RXCOND)The variables OBCOND, OPCOND, HHCOND, IPCOND, and ERCOND indicate that at least one 2024 event can be linked to the condition record on the current file, i.e., office-based, outpatient, home health, inpatient hospital stays, and emergency room visits. Note that the HHCOND variable includes all home health types, including informal care, and OBCOND and OPCOND include telehealth visits. The variable RXCOND is an indicator of any prescribed medicine purchase associated with the condition. These event indicators were derived from Expenditure Event PUFs (HC 254G, HC 254F, HC 254H, HC 254D, HC 254E, and HC 254A). Events associated with conditions include all utilization that occurred between January 1, 2024, and December 31, 2024. 3.0 Survey Sample Information3.1 Discussion of Pandemic Effects on Quality of MEPS DataLike most surveys, MEPS has been substantially affected by the COVID-19 pandemic. One effect of the pandemic is significantly lower response rates (see Section C.3.2 in the Consolidated PUF), which might differentially exclude households more likely to experience inpatient hospital stays. The demographic shifts on MEPS between 2019 and 2022 suggest a more educated, higher income, older MEPS sample. (For more details, see Section C.3.1 of the 2020 Consolidated PUF, Section C.3.1 of the 2021 Consolidated PUF, and Section C.3.1.2 of the 2022 Consolidated PUF.) MEPS sample design modifications due to the COVID-19 pandemic reverted in 2022. Thus, concerns about potential bias due to these modifications no longer apply to data collected in this PUF. To examine the quality of the MEPS full-year 2024 data, analyses compared healthcare utilization and health insurance coverage for the MEPS target population between the panels fielded. These comparisons were undertaken for the full sample and three age groups: 0-17, 18-64, and 65 or older. Analysts found no abnormal differences between the two panels. Analyses across years also suggest a rebound to pre-pandemic utilization levels for most essential event types. The development of the person-level weights for the MEPS full-year 2024 data was designed to limit the potential for response bias. However, analysts of the MEPS full-year 2024 data should continue to exercise caution when interpreting estimates and assessing analyses, especially for data collected from 2020 through 2022. This includes comparing estimates with those of other years and conducting corresponding trend analyses. 3.2 Sample Weight (PERWT24F)A single full-year person-level weight (PERWT24F) is assigned to each record for each Key in-scope person who responded to MEPS for the entire duration that they were in scope during 2024. A Key person was either a member of a responding NHIS household at the time of the interview or joined a family associated with such a household after being out of scope at the time of NHIS (the latter circumstance includes newborns and those returning from military service, an institution, or residence in a foreign country). A person is in scope whenever they are a member of the U.S. civilian noninstitutionalized population. 3.3 Details on Person Weight ConstructionThe person-level weight PERWT24F was developed in several stages. First, a person-level weight for Panel 28 was created, including an adjustment for nonresponse over time and raking. Raking involved adjusting to several sets of marginal control totals reflecting Current Population Survey (CPS) population estimates based on six variables. The six variables used to establish the initial person-level control figures include the following:
The person-level weight for Panel 29 was created similarly. A composite weight was formed by multiplying each weight from Panel 28 by the factor 0.44 and each weight from Panel 29 by the factor 0.56. The choice of factors reflects the relative effective sample sizes of the two panels, helping to limit the variance of estimates obtained from pooling both samples. Weights for the 2024 Consolidated PUF were then developed by raking the composite weight to CPS-based control totals, replacing educational attainment with poverty status while retaining the other five raking variables previously indicated. Specifically, control totals based on CPS estimates of poverty status (five categories: below poverty, 100% - 125% of poverty, 125% - 200% of poverty, 200% - 400% of poverty, at least 400% of poverty) in addition to age, race/ethnicity, sex, region, and MSA status are used to calibrate weights. 3.3.1 MEPS Panel 28 Weight Development ProcessThe person-level weight for Panel 28 was developed using the 2023 full-year weight as a “base” weight for survey participants present in 2024. For Key in-scope members who joined a reporting unit (RU) at some time in 2024 after being out of scope in 2023, the initially assigned person-level weight was the corresponding 2023 family weight. The weighting process also included an adjustment for person-level nonresponse over Rounds 4 and 5, as well as raking to the population control figures for December 2024 for Key responding persons in scope on December 31, 2024. These control totals were derived by scaling back the population distribution obtained from the March 2025 CPS to reflect the December 31, 2024, estimated population total (based on census projections for January 1, 2025). The six variables listed in Section C.3.3 were also used for person-level raking: education of the reference person, census region, MSA status, race/ethnicity, sex, and age. The final weight for Key responding persons who were not in scope on December 31, 2024, but were in scope earlier in the year was the nonresponse-adjusted person weight without raking. Note that the 2023 full-year weight that was used as the base weight for Panel 28 was derived using the 2023 MEPS Round 1 weight and reflected adjustment for nonresponse over the remaining data collection rounds in 2023, as well as raking to the December 2023 population control figures. 3.3.2 MEPS Panel 29 Weight Development ProcessThe person-level weight for Panel 29 was developed using the 2024 Round 1 person-level weight as a base weight. The Round 1 weights incorporated the following components: the original household probability of selection for NHIS and for the NHIS subsample reserved for MEPS, an adjustment for NHIS nonresponse, the probability of selection for MEPS from NHIS, an adjustment for nonresponse at the DU level for Round 1, and raking to control figures at the person level from the March CPS of the corresponding year. For Key in-scope members who joined an RU after Round 1, the Round 1 DU weight served as a base weight. The weighting process also included an adjustment for nonresponse over the remaining data collection rounds in 2024, as well as raking to the same population control figures for December 2024 that were used for the Panel 28 weight for Key responding persons in scope on December 31, 2024. The same six variables used for Panel 28 raking (education level of the reference person, census region, MSA status, race/ethnicity, sex, and age) were also used for Panel 29 raking. Similar to Panel 28, the Panel 29 final weight for Key responding persons who were not in scope on December 31, 2024, but were in scope earlier in the year was the nonresponse-adjusted person weight without raking. 3.3.3 The Final Weight for 2024The final raking of those in scope at the end of the year has been described previously. In addition, the composite weights of two groups of persons who were out of scope on December 31, 2024, were adjusted for expected undercoverage. Specifically, the weights of those who were out of scope on December 31, 2024, but in scope at some time during the year and were residing in a nursing home at the end of the year were poststratified to an estimate of the number of persons who were residents of Medicare- and Medicaid-certified nursing homes for part of the year (approximately 3-9 months) during 2014. This estimate was developed from data on the Minimum Data Set (MDS) of the Centers for Medicare & Medicaid Services (CMS). The weights of persons who died while in scope were poststratified to corresponding estimates derived using data from the Centers for Disease Control and Prevention (CDC), NCHS, and About Provisional Mortality Statistics, 2018 through Last Week on the CDC WONDER online database (released in 2025, the latest available data at the time). Separate decedent control totals were developed for the “65 or older” and “under 65” civilian noninstitutionalized populations. Overall, the weighted population estimate for the civilian noninstitutionalized population for December 31, 2024, is 336,022,966 (PERWT24F >0 and INSC1231 = 1). The sum of person-level weights across all persons assigned a positive person-level weight is 39,797,629. 3.4 CoverageThe target population associated with MEPS is the 2024 U.S. civilian noninstitutionalized population. However, the MEPS sampled households are a subsample of the NHIS households interviewed in 2022 (Panel 28) and 2023 (Panel 29). New households created after the NHIS interviews for the respective panels and consisting exclusively of persons who entered the target population after 2022 (Panel 28) or after 2023 (Panel 29) are not covered by the 2024 MEPS. Nor are previously out-of-scope persons who joined an existing household but are not related to the current household residents. Thus, persons not covered by a given MEPS panel include some members of the following groups: newborns, immigrants, persons leaving the military, U.S. citizens returning from residence in another country, and persons leaving institutions. Those not covered represent a small proportion of the MEPS target population. 3.5 Variance Estimation (VARSTR, VARPSU)To obtain estimates of variability in MEPS estimates (e.g., the standard error of sample estimates or corresponding confidence intervals), analysts should consider MEPS’s complex sample design for both person-level and family-level analyses. Several methods have been developed to estimate standard errors for surveys with complex sample designs, including the Taylor series linearization method, balanced repeated replication (BRR), and jackknife replication; various software packages can implement these methods. MEPS analysts most commonly use the Taylor series approach. Although this PUF does not contain replicate weights, analysts can use the BRR method to construct replicate weights to develop variances for more complex estimators (see Section C.3.5.2). VARSTR and VARPSU are included in the 2024 Jobs PUF for this purpose. 3.5.1 Taylor Series Linearization MethodThe variables needed to calculate appropriate standard errors based on the Taylor series linearization method are included on this file, as well as all other MEPS PUFs. Software packages that support the Taylor series linearization method include SUDAAN, R, Stata, SAS (version 8.2 or higher), and SPSS (version 12.0 or higher). For complete information on a package’s capabilities, analysts should refer to the software’s user documentation. With the Taylor series linearization method, variance estimation strata and the variance estimation primary sampling units (PSUs) within these strata must be specified. The variables VARSTR and VARPSU on this Jobs PUF identify the sampling strata and PSUs required by the variance estimation programs. Specifying a “with replacement” design in one of the previously mentioned software packages will provide estimated standard errors appropriate for assessing the variability of MEPS estimates. Note that the number of degrees of freedom associated with estimates of variability indicated by a package may not appropriately reflect the number available. For variables of interest distributed throughout the country (and thus across the MEPS sample PSUs), one can generally expect to see at least 100 degrees of freedom associated with the estimated standard errors for national estimates based on this MEPS database. Before 2002, the MEPS variance strata and PSUs were developed independently from year to year, and the last two characters of the strata and PSU variable names denoted the year. Beginning with the 2002 Point-in-Time PUF, the approach changed with the intention that variance strata and PSUs would be developed to be compatible with all future PUFs until the NHIS design changed. Thus, when pooling data from 2002 through Panel 11 in the 2007 files, analysts can use the variance strata and PSU variables provided without modifying them for variance estimation purposes for estimates covering multiple years of data. There are 203 variance estimation strata; each stratum has either two or three variance estimation PSUs. Beginning with Panel 12 in the 2007 files, a new set of variance strata and PSUs was developed because of the introduction of a new NHIS design. There are 165 variance strata with either two or three variance estimation PSUs per stratum. Therefore, there are a total of 368 (203 + 165) variance strata in the 2007 Consolidated PUF because it consists of two panels selected under two independent NHIS sample designs. Because both MEPS panels in the full-year files from 2008 to 2016 are based on the same NHIS design, there are only 165 variance strata. These strata (VARSTR values) have been numbered from 1001 to 1165 so they can be readily distinguished from those developed under the former NHIS sample design when pooling data across multiple years. The NHIS sample design was changed again in 2016, effectively changing the MEPS design beginning with calendar year 2017. Beginning with Panel 22 in the 2017 files, a new set of variance strata and PSUs was developed. There are 117 variance strata with either two or three variance estimation PSUs per stratum. Therefore, there are a total of 282 (165 + 117) variance strata in the 2017 Consolidated PUF because it consists of two panels selected under two independent NHIS sample designs. To simplify data pooling across multiple years of MEPS, the variance strata numbering system was changed. The strata associated with the new design are numbered from 2001 to 2117. The NHIS sample design was further modified in 2018, so the MEPS variance structure for the 2019 Consolidated PUF was also modified, reducing the number of variance strata to 105. The new variance structure maintained consistency with the prior structure by assigning the 2019 variance strata to values within the same 2001 to 2117 range, although there are now some gaps in the sequence of the assigned values. Because of the modification, each stratum could contain up to five variance estimation PSUs. For Panel 26 in the 2021 and 2022 Consolidated PUFs, an additional NHIS sample was used for MEPS to account for increasing nonresponse during the pandemic (as discussed in Section C.3.1.2). The additional sample was assigned to the existing variance strata, so the 2021 and 2022 Consolidated PUFs continued to have 105 variance strata, numbered from 2001 to 2117, though there are now some gaps in the values in that range. In many cases, the additional sample was assigned to new variance estimation PSUs. Thus, in the 2021 and 2022 Consolidated PUFs, each stratum contained up to eight variance estimation PSUs. Additional NHIS samples were no longer needed beginning in 2023, leading to fewer variance estimation PSUs than in the 2021 and 2022 Consolidated PUFs. The Consolidated PUF continues to have 105 variance strata, numbered from 2001 to 2117, with a few gaps in the values in that range. Each stratum contains up to seven variance estimation PSUs. When pooling data across multiple years of MEPS data, it is necessary to specify a common variance structure to obtain appropriate standard errors. Before 2002, each annual PUF was released with a variance structure unique to the particular MEPS sample in that year. Starting in 2002, the annual PUFs were released with a common variance structure to allow analysts to pool data from 2002 to 2018. However, analysts can no longer do this routinely because the variance structure was modified beginning in 2019. To ensure that variance strata are identified appropriately for variance estimation purposes when pooling MEPS data across several years, analysts should proceed as follows:
3.5.2 Balanced Repeated Replication MethodBRR replicate weights are not provided on this MEPS Jobs PUF for the purposes of variance estimation. However, a file containing a BRR structure is available so that analysts can form replicate weights, if desired, from the final MEPS weight to compute variances of MEPS estimates using either BRR or Fay’s modified BRR (Fay, 1989) methods. The replicate weights are useful for computing variances of complex nonlinear estimators for which a Taylor linear form is neither easy to derive nor available in commonly used software. For instance, it is not possible to calculate the variances of a median or the ratio of two medians by using the Taylor linearization method. For these types of estimators, analysts can calculate a variance using BRR or Fay’s modified BRR methods. However, it should be noted that the replicate weights are derived from the final weight through a shortcut approach. Specifically, the replicate weights are not computed from the base weight, and all adjustments made in different stages of weighting are not applied independently in each replicate. Thus, the variances computed using this one-step BRR do not capture the effects of all weighting adjustments that would be captured in a set of fully developed BRR replicate weights. The Taylor series approach does not fully capture the effects of the different weighting adjustments, either. The dataset HC-036BRR: MEPS 1996-2024 Replicates for Variance Estimation File contains the information necessary to construct the BRR replicates. It includes a set of 128 flags (BRR1-BRR128) in the form of half-sample indicators, each of which is coded 0 or 1 to indicate whether the person should or should not be included in that particular replicate. These flags can be used in conjunction with the full-year weight to construct the BRR replicate weights. For an analysis of MEPS data pooled across years, the BRR replicates can be formed in the same way by using the HC-036: MEPS 1996-2024 Pooled Linkage Variance Estimation File. 3.6 Using MEPS Data for Trend AnalysisFor analysts using the MEPS data for trend analysis, there are uncertainties associated with 2020, 2021, and 2022 data quality, as discussed in Section C.3.1. Evaluations of important MEPS estimates suggest that the estimates are of reasonable quality. Nevertheless, analysts are advised to exercise caution when interpreting these estimates, particularly for trend analyses, because the pandemic substantially affected healthcare access and related factors (e.g., health insurance coverage, employment status). MEPS began in 1996, and the utility of the survey for analyzing healthcare trends expands with each additional year of data; however, when examining trends over time using MEPS, the duration being analyzed should be considered. In particular, large shifts in survey estimates over short periods (e.g., from one year to the next) that are statistically significant should be interpreted with caution, unless they are attributable to known factors such as changes in public policy, economic conditions, or the MEPS methodology. With respect to methodological considerations, changes in data collection methods, such as interviewer training, were introduced in 2013 to obtain more complete information about healthcare utilization from MEPS respondents; the changes were fully implemented in 2014. This effort likely improved data quality and reduced underreporting starting in the second half of 2013 and continuing throughout the 2014 full-year files. The changes have also affected analyses involving utilization trends across years. Changes in the NHIS sample design in 2016 and 2018 could also affect trend analyses. The new NHIS sample design is based on more up-to-date information related to the distribution of housing units across the United States. As a result, it can be expected to better cover the full civilian noninstitutionalized population, the target population for MEPS, and many of its subpopulations. Improved coverage of the target population helps to reduce the potential for bias in both NHIS and MEPS estimates. Another change with the potential to affect trend analyses involves major modifications to the MEPS instrument design and data collection process, particularly in the events sections of the instrument. These were introduced in spring 2018 and thus affected data beginning with Round 1 of Panel 23, Round 3 of Panel 22, and Round 5 of Panel 21. Because the full-year 2017 MEPS files were established from data collected in Rounds 1-3 of Panel 22 and Rounds 3-5 of Panel 21, they reflect two instrument designs. To mitigate the effect of such differences within the same full-year file, the Panel 22 Round 3 data and the Panel 21 Round 5 data were transformed to be as consistent as possible with data collected under the previous design. The changes to the instrument were designed to make data collection more efficient and easier to administer. In addition, data on some items, such as those related to healthcare events, were expected to be more complete, with the potential of identifying more events. Increases in service use reported since the implementation of these changes are consistent with these expectations. Note: Analysts should be aware of the possible impacts of these changes on data, especially trend analyses, that include the year 2018 because of the design transition. Process changes, such as data editing and imputation, may also affect trend analyses. For example, analysts should refer to Section C.2.5.11: Utilization, Expenditures, and Sources of Payment Variables in the Consolidated PUF (HC 256). For more details, refer to the documentation for the prescription drug file (HC 254A) when analyzing prescription drug spending over time. As always, before conducting trend analyses, analysts should review relevant documentation sections for descriptions of changes that might affect interpretation over time. To smooth or stabilize trend analyses based on MEPS data, analysts may also wish to consider statistical approaches such as comparing pooled time periods (e.g., 1996-1997 vs. 2011-2012), working with moving averages, or using modeling techniques with several consecutive years of data. Finally, statistical significance tests should be conducted to assess the likelihood that observed trends are not attributable to sampling variation. In addition, researchers should be aware of the impact of multiple comparisons on Type I error. Without making appropriate allowance for multiple comparisons, conducting numerous statistical significance tests of trends will increase the likelihood of concluding that a change has occurred when one has not. 4.0 National Health Interview Survey (NHIS)Data from this PUF can be used alone or in conjunction with other PUFs for different analytic purposes. Each MEPS panel can also be linked back to the previous years’ NHIS PUFs. This is because the set of households selected for MEPS is a subsample of NHIS participants. For information on obtaining MEPS/NHIS link files please see the data files section of the MEPS website. 5.0 Longitudinal AnalysisPanel-specific longitudinal files can be downloaded from the data section of the MEPS website. For both panels (Panel 28 and Panel 29), the longitudinal file comprises MEPS data obtained in all rounds of the panel and can be used to analyze changes over the entire length of the panel. Variables on the PUF pertaining to survey administration, demographics, employment, health status, disability days, quality of care, patient satisfaction, health insurance, and medical care use and expenditures were obtained from the MEPS Consolidated PUF from the years covered by that panel. For more details or to download the data files, please see Longitudinal Data Files on the MEPS website. ReferencesChowdhury, S. R., Machlin, S. R., & Gwet, K. L. (2019, January) Sample designs of the Medical Expenditure Panel Survey Household Component, 1996-2006 and 2007-2016. (Methodology Report #33). Agency for Healthcare Research and Quality. Health Care Financing Administration (1980). International Classification of Diseases, 9th Revision, Clinical Modification (ICD-CM). Vol. 1. (Department of Health and Human Services Pub. No (PHS) 80-1260). Department of Health and Human Services: U.S. Public Health Services. U.S. Census Bureau (2021). Current Population Survey: 2021 Annual Social and Economic (ASEC) Supplement. U.S. Census Bureau, Bureau of Labor Statistics. Additional ResourcesBramlett, M. D., Dahlhamer, J. M., & Bose, J. (2021, September). Weighting Procedures and bias assessment for the 2020 National Health Interview Survey. National Center for Health Statistics. Cox, B., & Iachan, R. (1987). A Comparison of Household and Provider Reports of Medical Conditions. Journal of the American Statistical Association, 82(400): 1013-18. Dahlhamer, J. M., Bramlett, M. D., Maitland, A., & Blumberg, S. J. (2021, February). Preliminary evaluation of nonresponse bias due to the COVID-19 pandemic on National Health Interview Survey estimates, April-June 2020. National Center for Health Statistics. Edwards, W. S., Winn, D. M., Kurlantzick, V., et al. (1994), Evaluation of National Health Interview Survey Diagnostic Reporting. National Center for Health Statistics, Vital Health (Series 2. No. 120). Johnson, A.E., & Sanchez, M.E. (1993), Household and Medical Provider Reports on Medical Conditions: National Medical Expenditure Survey, 1987. Journal of Economic and Social Measurement, 19 (3), pp. 199-223. Lau, D. T., Sosa, P., Dasgupta, N., & He, H. (2021). Impact of the COVID-19 pandemic on public health surveillance and survey data collections in the United States. American Journal of Public Health, 111 (12), pp. 2118-2121. Rothbaum, J., & Bee, A. (2021, May). Coronavirus infects surveys, too: Survey nonresponse bias and the coronavirus pandemic. U.S. Census Bureau. Rothbaum, J., & Bee, A. (2022, September). How has the pandemic continued to affect survey response? Using administrative data to evaluate nonresponse in the 2022 Current Population Survey Annual Social and Economic Supplement. U.S. Census Bureau. Zuvekas, S. H., & Kashihara, D. (2021). The impacts of the COVID-19 pandemic on the Medical Expenditure Panel Survey. American Journal of Public Health, 111 (12), pp. 2157-2166. Appendix 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Variable | Label | Source |
|---|---|---|
| DUID | PANEL # + ENCRYPTED DU IDENTIFIER | Assigned In Sampling |
| PID | PERSON NUMBER | Assigned In Sampling |
| DUPERSID | PERSON ID (DUID + PID) | Assigned In Sampling |
| CONDN | CONDITION NUMBER | CAPI Derived |
| CONDIDX | CONDITION ID | CAPI Derived |
| PANEL | PANEL NUMBER | Constructed |
| CONDRN | CONDITION ROUND NUMBER | CAPI Derived |
| Variable | Label | Source |
|---|---|---|
| AGEDIAG | AGE WHEN DIAGNOSED | PE section |
| CRND1 | HAS CONDITION INFORMATION IN ROUND 1 | Constructed |
| CRND2 | HAS CONDITION INFORMATION IN ROUND 2 | Constructed |
| CRND3 | HAS CONDITION INFORMATION IN ROUND 3 | Constructed |
| CRND4 | HAS CONDITION INFORMATION IN ROUND 4 | Constructed |
| CRND5 | HAS CONDITION INFORMATION IN ROUND 5 | Constructed |
| INJURY | WAS CONDITION DUE TO ACCIDENT/INJURY | AH80 |
| ACCDNWRK | DID ACCIDENT OCCUR AT WORK | AH90 |
| ICD10CDX | ICD-10-CM CODE FOR CONDITION - EDITED | HS40, ER30, OP60, MV70, HH80, PM120, PE Section (Edited) |
| CCSR1X | CLINICAL CLASSIFICATION REFINED CODE 1 EDITED | HS40, ER30, OP60, MV70, HH80, PM120, PE section (Edited) |
| CCSR2X | CLINICAL CLASSIFICATION REFINED CODE 2 EDITED | HS40, ER30, OP60, MV70, HH80, PM120, PE section (Edited) |
| CCSR3X | CLINICAL CLASSIFICATION REFINED CODE 3 EDITED | HS40, ER30, OP60, MV70, HH80, PM120, PE section (Edited) |
| CCSR4X | CLINICAL CLASSIFICATION REFINED CODE 4 EDITED | HS40, ER30, OP60, MV70, HH80, PM120, PE section (Edited) |
| Variable | Label | Source |
|---|---|---|
| HHCOND | ANY HOME HEALTH EVENTS ASSOC. W/ CONDITION? | Constructed |
| IPCOND | ANY INPATIENT EVENTS ASSOC. W/ CONDITION? | Constructed |
| OPCOND | ANY OUTPATIENT EVENTS ASSOC. W/ CONDITION? | Constructed |
| OBCOND | ANY OFFICE-BASED EVENTS ASSOC W/ CONDITION? | Constructed |
| ERCOND | ANY ER EVENTS ASSOC. W/ CONDITION? | Constructed |
| RXCOND | ANY PRESCRIBED MEDICINES ASSOC. W/ COND.? | Constructed |
| Variable | Label | Source |
|---|---|---|
| PERWT24F | EXPENDITURE FILE PERSON WEIGHT, 2024 | Constructed |
| VARSTR | VARIANCE ESTIMATION STRATUM, 2024 | Constructed |
| VARPSU | VARIANCE ESTIMATION PSU, 2024 | Constructed |
| ICD10CDX VALUE | ICD10CDX LABEL | UNWEIGHTED | WEIGHTED BY perwt24f |
|---|---|---|---|
| -15 | CANNOT BE COMPUTED | 7631 | 125082614.85 |
| A08 | VIRAL AND OTHER SPECIFIED INTESTINAL INFECTIONS | 116 | 2302559.66 |
| A49 | BACTERIAL INFECTION OF UNSPECIFIED SITE | 85 | 1388127.46 |
| B00 | HERPESVIRAL [HERPES SIMPLEX] INFECTIONS | 80 | 1437910.43 |
| B02 | ZOSTER [HERPES ZOSTER] | 55 | 912845.39 |
| B07 | VIRAL WARTS | 75 | 1376627.55 |
| B34 | VIRAL INFECTION OF UNSPECIFIED SITE | 114 | 2212994.39 |
| B35 | DERMATOPHYTOSIS | 135 | 2032911.40 |
| B37 | CANDIDIASIS | 53 | 973858.56 |
| C34 | MALIGNANT NEOPLASM OF BRONCHUS AND LUNG | 45 | 569597.04 |
| C43 | MALIGNANT MELANOMA OF SKIN | 149 | 2094294.08 |
| C44 | OTHER AND UNSPECIFIED MALIGNANT NEOPLASM OF SKIN | 444 | 6357952.60 |
| C50 | MALIGNANT NEOPLASM OF BREAST | 196 | 2719565.53 |
| C61 | MALIGNANT NEOPLASM OF PROSTATE | 182 | 2465915.58 |
| C73 | MALIGNANT NEOPLASM OF THYROID GLAND | 55 | 819515.92 |
| C95 | LEUKEMIA OF UNSPECIFIED CELL TYPE | 40 | 487067.31 |
| D04 | CARCINOMA IN SITU OF SKIN | 137 | 2114158.62 |
| D22 | MELANOCYTIC NEVI | 69 | 1105494.89 |
| D49 | NEOPLASMS OF UNSPECIFIED BEHAVIOR | 114 | 1459604.32 |
| D50 | IRON DEFICIENCY ANEMIA | 66 | 917397.63 |
| D64 | OTHER ANEMIAS | 107 | 1452015.72 |
| E03 | OTHER HYPOTHYROIDISM | 859 | 13149647.11 |
| E04 | OTHER NONTOXIC GOITER | 108 | 1536332.01 |
| E05 | THYROTOXICOSIS [HYPERTHYROIDISM] | 159 | 2462499.73 |
| E06 | THYROIDITIS | 125 | 1888036.88 |
| E07 | OTHER DISORDERS OF THYROID | 222 | 2950596.46 |
| E11 | TYPE 2 DIABETES MELLITUS | 2076 | 29563349.62 |
| E28 | OVARIAN DYSFUNCTION | 54 | 1113607.67 |
| E29 | TESTICULAR DYSFUNCTION | 74 | 1272879.06 |
| E34 | OTHER ENDOCRINE DISORDERS | 105 | 1712554.54 |
| E53 | DEFICIENCY OF OTHER B GROUP VITAMINS | 90 | 1441968.06 |
| E55 | VITAMIN D DEFICIENCY | 352 | 5533766.93 |
| E61 | DEFICIENCY OF OTHER NUTRIENT ELEMENTS | 142 | 2166748.18 |
| E66 | OVERWEIGHT AND OBESITY | 224 | 3881240.27 |
| E78 | DISORDERS OF LIPOPROTEIN METABOLISM AND OTHER LIPIDEMIAS | 3667 | 51513465.51 |
| E83 | DISORDERS OF MINERAL METABOLISM | 56 | 705544.90 |
| E86 | VOLUME DEPLETION | 61 | 853314.16 |
| E87 | OTHER DISORDERS OF FLUID, ELECTROLYTE AND ACID-BASE BALANCE | 254 | 3130627.61 |
| F03 | UNSPECIFIED DEMENTIA | 79 | 1016387.89 |
| F20 | SCHIZOPHRENIA | 47 | 584602.53 |
| F31 | BIPOLAR DISORDER | 203 | 3265301.02 |
| F32 | DEPRESSIVE EPISODE | 1649 | 27393709.13 |
| F39 | UNSPECIFIED MOOD [AFFECTIVE] DISORDER | 49 | 816812.35 |
| F41 | OTHER ANXIETY DISORDERS | 1957 | 34186403.14 |
| F42 | OBSESSIVE-COMPULSIVE DISORDER | 59 | 1155530.54 |
| F43 | REACTION TO SEVERE STRESS, AND ADJUSTMENT DISORDERS | 396 | 6973866.38 |
| F84 | PERVASIVE DEVELOPMENTAL DISORDERS | 127 | 2566301.33 |
| F90 | ATTENTION-DEFICIT HYPERACTIVITY DISORDERS | 677 | 13384307.14 |
| F99 | MENTAL DISORDER, NOT OTHERWISE SPECIFIED | 348 | 6492536.35 |
| G20 | PARKINSON'S DISEASE | 62 | 637710.82 |
| G25 | OTHER EXTRAPYRAMIDAL AND MOVEMENT DISORDERS | 124 | 1756518.33 |
| G35 | MULTIPLE SCLEROSIS | 50 | 839734.36 |
| G40 | EPILEPSY AND RECURRENT SEIZURES | 97 | 1549774.17 |
| G43 | MIGRAINE | 389 | 6538388.37 |
| G45 | TRANSIENT CEREBRAL ISCHEMIC ATTACKS AND RELATED SYNDROMES | 230 | 3029377.18 |
| G47 | SLEEP DISORDERS | 1201 | 18206528.65 |
| G56 | MONONEUROPATHIES OF UPPER LIMB | 90 | 1310488.39 |
| G57 | MONONEUROPATHIES OF LOWER LIMB | 97 | 1253090.64 |
| G62 | OTHER AND UNSPECIFIED POLYNEUROPATHIES | 282 | 3809475.57 |
| G89 | PAIN, NOT ELSEWHERE CLASSIFIED | 301 | 4693906.89 |
| H00 | HORDEOLUM AND CHALAZION | 43 | 700168.86 |
| H02 | OTHER DISORDERS OF EYELID | 43 | 557100.55 |
| H04 | DISORDERS OF LACRIMAL SYSTEM | 227 | 3110003.18 |
| H10 | CONJUNCTIVITIS | 132 | 2444646.66 |
| H26 | OTHER CATARACT | 572 | 7279278.82 |
| H33 | RETINAL DETACHMENTS AND BREAKS | 51 | 706834.34 |
| H35 | OTHER RETINAL DISORDERS | 253 | 3257381.20 |
| H40 | GLAUCOMA | 345 | 4723195.20 |
| H43 | DISORDERS OF VITREOUS BODY | 46 | 640217.09 |
| H44 | DISORDERS OF GLOBE | 58 | 902087.06 |
| H52 | DISORDERS OF REFRACTION AND ACCOMMODATION | 295 | 5785183.58 |
| H53 | VISUAL DISTURBANCES | 127 | 2147675.93 |
| H54 | BLINDNESS AND LOW VISION | 128 | 1930021.84 |
| H57 | OTHER DISORDERS OF EYE AND ADNEXA | 190 | 2824265.87 |
| H61 | OTHER DISORDERS OF EXTERNAL EAR | 98 | 1432668.66 |
| H66 | SUPPURATIVE AND UNSPECIFIED OTITIS MEDIA | 396 | 8017189.91 |
| H91 | OTHER AND UNSPECIFIED HEARING LOSS | 284 | 4272524.60 |
| H92 | OTALGIA AND EFFUSION OF EAR | 77 | 1321212.33 |
| H93 | OTHER DISORDERS OF EAR, NOT ELSEWHERE CLASSIFIED | 65 | 1081204.31 |
| I10 | ESSENTIAL (PRIMARY) HYPERTENSION | 4357 | 61741124.31 |
| I21 | ACUTE MYOCARDIAL INFARCTION | 288 | 3972551.36 |
| I25 | CHRONIC ISCHEMIC HEART DISEASE | 537 | 7340281.63 |
| I26 | PULMONARY EMBOLISM | 57 | 938711.49 |
| I38 | ENDOCARDITIS, VALVE UNSPECIFIED | 108 | 1513476.51 |
| I48 | ATRIAL FIBRILLATION AND FLUTTER | 357 | 4718233.45 |
| I49 | OTHER CARDIAC ARRHYTHMIAS | 240 | 3300710.50 |
| I50 | HEART FAILURE | 146 | 1830758.68 |
| I51 | COMPLICATIONS AND ILL-DEFINED DESCRIPTIONS OF HEART DISEASE | 161 | 2295297.21 |
| I63 | CEREBRAL INFARCTION | 42 | 504629.00 |
| I73 | OTHER PERIPHERAL VASCULAR DISEASES | 42 | 586778.62 |
| I74 | ARTERIAL EMBOLISM AND THROMBOSIS | 228 | 3040509.53 |
| I83 | VARICOSE VEINS OF LOWER EXTREMITIES | 43 | 602339.75 |
| I95 | HYPOTENSION | 57 | 662006.31 |
| I99 | OTHER AND UNSPECIFIED DISORDERS OF CIRCULATORY SYSTEM | 54 | 630483.31 |
| J00 | ACUTE NASOPHARYNGITIS [COMMON COLD] | 240 | 4547658.64 |
| J02 | ACUTE PHARYNGITIS | 450 | 8701516.44 |
| J06 | ACUTE UPPER RESP INFECTIONS OF MULTIPLE AND UNSP SITES | 80 | 1280688.80 |
| J11 | INFLUENZA DUE TO UNIDENTIFIED INFLUENZA VIRUS | 274 | 5071178.96 |
| J18 | PNEUMONIA, UNSPECIFIED ORGANISM | 275 | 4299767.53 |
| J20 | ACUTE BRONCHITIS | 63 | 1098157.00 |
| J30 | VASOMOTOR AND ALLERGIC RHINITIS | 918 | 13729624.20 |
| J32 | CHRONIC SINUSITIS | 428 | 7105378.59 |
| J34 | OTHER AND UNSPECIFIED DISORDERS OF NOSE AND NASAL SINUSES | 139 | 2193453.80 |
| J39 | OTHER DISEASES OF UPPER RESPIRATORY TRACT | 84 | 1403683.83 |
| J40 | BRONCHITIS, NOT SPECIFIED AS ACUTE OR CHRONIC | 143 | 2413340.38 |
| J42 | UNSPECIFIED CHRONIC BRONCHITIS | 84 | 1049935.98 |
| J43 | EMPHYSEMA | 77 | 997272.20 |
| J44 | OTHER CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 219 | 2697550.67 |
| J45 | ASTHMA | 1247 | 19410818.09 |
| J98 | OTHER RESPIRATORY DISORDERS | 195 | 3388232.21 |
| K04 | DISEASES OF PULP AND PERIAPICAL TISSUES | 103 | 1845236.11 |
| K08 | OTHER DISORDERS OF TEETH AND SUPPORTING STRUCTURES | 218 | 3914000.22 |
| K21 | GASTRO-ESOPHAGEAL REFLUX DISEASE | 1243 | 18318882.92 |
| K22 | OTHER DISEASES OF ESOPHAGUS | 71 | 963250.53 |
| K25 | GASTRIC ULCER | 63 | 983946.85 |
| K29 | GASTRITIS AND DUODENITIS | 90 | 1136438.72 |
| K30 | FUNCTIONAL DYSPEPSIA | 151 | 2031486.22 |
| K31 | OTHER DISEASES OF STOMACH AND DUODENUM | 83 | 1329319.00 |
| K46 | UNSPECIFIED ABDOMINAL HERNIA | 82 | 1057931.60 |
| K52 | OTHER AND UNSP NONINFECTIVE GASTROENTERITIS AND COLITIS | 59 | 912257.27 |
| K57 | DIVERTICULAR DISEASE OF INTESTINE | 77 | 1023506.66 |
| K58 | IRRITABLE BOWEL SYNDROME | 101 | 1761898.39 |
| K59 | OTHER FUNCTIONAL INTESTINAL DISORDERS | 183 | 2837969.58 |
| K63 | OTHER DISEASES OF INTESTINE | 163 | 2279840.71 |
| K64 | HEMORRHOIDS AND PERIANAL VENOUS THROMBOSIS | 50 | 755648.26 |
| K76 | OTHER DISEASES OF LIVER | 115 | 1839540.48 |
| K82 | OTHER DISEASES OF GALLBLADDER | 63 | 1016646.49 |
| K92 | OTHER DISEASES OF DIGESTIVE SYSTEM | 88 | 1265107.19 |
| L03 | CELLULITIS AND ACUTE LYMPHANGITIS | 59 | 1042882.17 |
| L08 | OTHER LOCAL INFECTIONS OF SKIN AND SUBCUTANEOUS TISSUE | 154 | 2575946.21 |
| L23 | ALLERGIC CONTACT DERMATITIS | 97 | 1791850.62 |
| L29 | PRURITUS | 76 | 1089378.85 |
| L30 | OTHER AND UNSPECIFIED DERMATITIS | 225 | 4018332.26 |
| L40 | PSORIASIS | 104 | 1545256.76 |
| L60 | NAIL DISORDERS | 189 | 2806739.83 |
| L65 | OTHER NONSCARRING HAIR LOSS | 103 | 1826102.72 |
| L70 | ACNE | 185 | 3928307.66 |
| L71 | ROSACEA | 83 | 1267380.57 |
| L72 | FOLLICULAR CYSTS OF SKIN AND SUBCUTANEOUS TISSUE | 101 | 1522864.23 |
| L84 | CORNS AND CALLOSITIES | 76 | 1101183.77 |
| L90 | ATROPHIC DISORDERS OF SKIN | 47 | 737348.55 |
| L91 | HYPERTROPHIC DISORDERS OF SKIN | 49 | 756732.57 |
| L98 | OTH DISORDERS OF SKIN, SUBCU, NOT ELSEWHERE CLASSIFIED | 361 | 5759240.68 |
| M06 | OTHER RHEUMATOID ARTHRITIS | 321 | 3939556.01 |
| M10 | GOUT | 262 | 3539487.47 |
| M17 | OSTEOARTHRITIS OF KNEE | 139 | 2272220.63 |
| M19 | OTHER AND UNSPECIFIED OSTEOARTHRITIS | 1174 | 15652309.09 |
| M21 | OTHER ACQUIRED DEFORMITIES OF LIMBS | 65 | 960293.98 |
| M25 | OTHER JOINT DISORDER, NOT ELSEWHERE CLASSIFIED | 1558 | 23615429.25 |
| M32 | SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | 47 | 724952.05 |
| M35 | OTHER SYSTEMIC INVOLVEMENT OF CONNECTIVE TISSUE | 66 | 1042226.99 |
| M41 | SCOLIOSIS | 67 | 1097303.62 |
| M43 | OTHER DEFORMING DORSOPATHIES | 47 | 704837.57 |
| M48 | OTHER SPONDYLOPATHIES | 101 | 1368583.88 |
| M50 | CERVICAL DISC DISORDERS | 51 | 761120.37 |
| M51 | THORACIC, THORACOLUM, AND LUMBOSACRAL INTVRT DISC DISORDERS | 239 | 3515722.13 |
| M53 | OTHER AND UNSPECIFIED DORSOPATHIES, NOT ELSEWHERE CLASSIFIED | 123 | 1830323.15 |
| M54 | DORSALGIA | 1575 | 24180300.26 |
| M62 | OTHER DISORDERS OF MUSCLE | 223 | 3250044.95 |
| M65 | SYNOVITIS AND TENOSYNOVITIS | 66 | 897557.98 |
| M71 | OTHER BURSOPATHIES | 62 | 817231.07 |
| M72 | FIBROBLASTIC DISORDERS | 83 | 1354326.31 |
| M75 | SHOULDER LESIONS | 80 | 1074312.57 |
| M77 | OTHER ENTHESOPATHIES | 94 | 1561040.16 |
| M79 | OTH AND UNSP SOFT TISSUE DISORDERS, NOT ELSEWHERE CLASSIFIED | 946 | 13506763.88 |
| M81 | OSTEOPOROSIS WITHOUT CURRENT PATHOLOGICAL FRACTURE | 222 | 2881356.14 |
| M85 | OTHER DISORDERS OF BONE DENSITY AND STRUCTURE | 237 | 3330129.94 |
| M89 | OTHER DISORDERS OF BONE | 42 | 689983.75 |
| N19 | UNSPECIFIED KIDNEY FAILURE | 66 | 816288.33 |
| N20 | CALCULUS OF KIDNEY AND URETER | 157 | 2398252.20 |
| N28 | OTH DISORDERS OF KIDNEY AND URETER, NOT ELSEWHERE CLASSIFIED | 214 | 2849609.30 |
| N30 | CYSTITIS | 60 | 785468.80 |
| N32 | OTHER DISORDERS OF BLADDER | 151 | 1905604.43 |
| N39 | OTHER DISORDERS OF URINARY SYSTEM | 565 | 8821277.95 |
| N40 | BENIGN PROSTATIC HYPERPLASIA | 316 | 4432945.97 |
| N42 | OTHER AND UNSPECIFIED DISORDERS OF PROSTATE | 94 | 1351309.68 |
| N52 | MALE ERECTILE DYSFUNCTION | 83 | 1325085.15 |
| N63 | UNSPECIFIED LUMP IN BREAST | 62 | 1159601.15 |
| N81 | FEMALE GENITAL PROLAPSE | 66 | 1041855.68 |
| N83 | NONINFLAMMATORY DISORD OF OVARY, FALLOP AND BROAD LIGAMENT | 46 | 785506.29 |
| N89 | OTHER NONINFLAMMATORY DISORDERS OF VAGINA | 52 | 771969.38 |
| N92 | EXCESSIVE, FREQUENT AND IRREGULAR MENSTRUATION | 79 | 1826087.18 |
| R00 | ABNORMALITIES OF HEART BEAT | 189 | 2614621.41 |
| R01 | CARDIAC MURMURS AND OTHER CARDIAC SOUNDS | 61 | 749061.85 |
| R03 | ABNORMAL BLOOD-PRESSURE READING, WITHOUT DIAGNOSIS | 58 | 901477.60 |
| R05 | COUGH | 301 | 4857453.92 |
| R06 | ABNORMALITIES OF BREATHING | 226 | 3041788.42 |
| R07 | PAIN IN THROAT AND CHEST | 143 | 2026408.90 |
| R09 | OTH SYMPTOMS AND SIGNS INVOLVING THE CIRC AND RESP SYS | 72 | 960484.66 |
| R10 | ABDOMINAL AND PELVIC PAIN | 268 | 4226306.79 |
| R11 | NAUSEA AND VOMITING | 285 | 4652634.65 |
| R12 | HEARTBURN | 160 | 2185065.44 |
| R19 | OTH SYMPTOMS AND SIGNS INVOLVING THE DGSTV SYS AND ABDOMEN | 76 | 1038448.74 |
| R20 | DISTURBANCES OF SKIN SENSATION | 53 | 733789.04 |
| R21 | RASH AND OTHER NONSPECIFIC SKIN ERUPTION | 240 | 3913817.85 |
| R22 | LOCALIZED SWELLING, MASS AND LUMP OF SKIN, SUBCU | 69 | 1092950.22 |
| R25 | ABNORMAL INVOLUNTARY MOVEMENTS | 166 | 2200335.92 |
| R26 | ABNORMALITIES OF GAIT AND MOBILITY | 113 | 1341306.58 |
| R32 | UNSPECIFIED URINARY INCONTINENCE | 132 | 1659586.90 |
| R39 | OTH AND UNSP SYMPTOMS AND SIGNS INVOLVING THE GU SYS | 44 | 553962.35 |
| R41 | OTH SYMPTOMS AND SIGNS W COGNITIVE FUNCTIONS AND AWARENESS | 140 | 1920535.11 |
| R42 | DIZZINESS AND GIDDINESS | 229 | 2994045.36 |
| R45 | SYMPTOMS AND SIGNS INVOLVING EMOTIONAL STATE | 57 | 894612.00 |
| R47 | SPEECH DISTURBANCES, NOT ELSEWHERE CLASSIFIED | 56 | 1040472.36 |
| R50 | FEVER OF OTHER AND UNKNOWN ORIGIN | 100 | 1847284.05 |
| R51 | HEADACHE | 147 | 2250137.19 |
| R52 | PAIN, UNSPECIFIED | 115 | 1748325.15 |
| R53 | MALAISE AND FATIGUE | 77 | 1055280.23 |
| R54 | AGE-RELATED PHYSICAL DEBILITY | 62 | 713243.45 |
| R56 | CONVULSIONS, NOT ELSEWHERE CLASSIFIED | 78 | 1005446.73 |
| R60 | EDEMA, NOT ELSEWHERE CLASSIFIED | 282 | 3752677.99 |
| R63 | SYMPTOMS AND SIGNS CONCERNING FOOD AND FLUID INTAKE | 83 | 1409207.32 |
| R73 | ELEVATED BLOOD GLUCOSE LEVEL | 318 | 5069273.98 |
| R91 | ABNORMAL FINDINGS ON DIAGNOSTIC IMAGING OF LUNG | 58 | 729197.40 |
| R92 | ABNORMAL AND INCONCLUSIVE FINDINGS ON DX IMAGING OF BREAST | 44 | 682053.16 |
| S01 | OPEN WOUND OF HEAD | 43 | 675279.93 |
| S06 | INTRACRANIAL INJURY | 73 | 1148919.68 |
| S09 | OTHER AND UNSPECIFIED INJURIES OF HEAD | 49 | 857403.34 |
| S39 | OTH & UNSP INJURIES OF ABD, LOW BACK, PELV & EXTRN GENITALS | 101 | 1596951.24 |
| S42 | FRACTURE OF SHOULDER AND UPPER ARM | 68 | 1156043.61 |
| S49 | OTHER AND UNSPECIFIED INJURIES OF SHOULDER AND UPPER ARM | 88 | 1541787.51 |
| S61 | OPEN WOUND OF WRIST, HAND AND FINGERS | 56 | 822743.14 |
| S62 | FRACTURE AT WRIST AND HAND LEVEL | 76 | 1250695.35 |
| S69 | OTHER AND UNSPECIFIED INJURIES OF WRIST, HAND AND FINGER(S) | 88 | 1532185.78 |
| S82 | FRACTURE OF LOWER LEG, INCLUDING ANKLE | 87 | 1368199.41 |
| S83 | DISLOCATION AND SPRAIN OF JOINTS AND LIGAMENTS OF KNEE | 81 | 1247191.50 |
| S89 | OTHER AND UNSPECIFIED INJURIES OF LOWER LEG | 104 | 1687533.37 |
| S92 | FRACTURE OF FOOT AND TOE, EXCEPT ANKLE | 62 | 1002945.50 |
| S93 | DISLOC & SPRAIN OF JOINTS & LIGAMENTS AT ANKL, FT & TOE LEV | 73 | 1374300.14 |
| S99 | OTHER AND UNSPECIFIED INJURIES OF ANKLE AND FOOT | 83 | 1451886.32 |
| T14 | INJURY OF UNSPECIFIED BODY REGION | 320 | 4638159.03 |
| T63 | TOXIC EFFECT OF CONTACT WITH VENOMOUS ANIMALS AND PLANTS | 71 | 1138603.22 |
| T78 | ADVERSE EFFECTS, NOT ELSEWHERE CLASSIFIED | 297 | 4963077.41 |
| T88 | OTH COMPLICATIONS OF SURGICAL AND MEDICAL CARE, NEC | 45 | 709473.29 |
| U07 | EMERGENCY USE OF U07 | 557 | 8915411.81 |
| U09 | POST COVID-19 CONDITION | 80 | 1141411.04 |
| Z00 | ENCNTR FOR GENERAL EXAM W/O COMPLAINT, SUSP OR REPRTD DX | 327 | 5559135.14 |
| Z01 | ENCNTR FOR OTH SP EXAM W/O COMPLAINT, SUSPECTED OR REPRTD DX | 127 | 1935233.66 |
| Z04 | ENCOUNTER FOR EXAMINATION AND OBSERVATION FOR OTHER REASONS | 57 | 1084253.81 |
| Z09 | ENCNTR FOR F/U EXAM AFT TRTMT FOR COND OTH THAN MALIG NEOPLM | 51 | 761017.61 |
| Z12 | ENCOUNTER FOR SCREENING FOR MALIGNANT NEOPLASMS | 274 | 4000157.05 |
| Z13 | ENCOUNTER FOR SCREENING FOR OTHER DISEASES AND DISORDERS | 179 | 2428391.99 |
| Z21 | ASYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS INFECTION STATUS | 41 | 519624.86 |
| Z23 | ENCOUNTER FOR IMMUNIZATION | 387 | 6348720.49 |
| Z29 | ENCOUNTER FOR OTHER PROPHYLACTIC MEASURES | 129 | 1708428.95 |
| Z30 | ENCOUNTER FOR CONTRACEPTIVE MANAGEMENT | 269 | 6030842.30 |
| Z34 | ENCOUNTER FOR SUPERVISION OF NORMAL PREGNANCY | 190 | 3900588.71 |
| Z38 | LIVEBORN INFANTS ACCORDING TO PLACE OF BIRTH AND TYPE OF DEL | 42 | 963325.80 |
| Z48 | ENCOUNTER FOR OTHER POSTPROCEDURAL AFTERCARE | 64 | 868719.21 |
| Z51 | ENCOUNTER FOR OTHER AFTERCARE AND MEDICAL CARE | 46 | 607611.57 |
| Z63 | OTH PROB REL TO PRIM SUPPORT GROUP, INC FAMILY CIRCUMSTANCES | 85 | 1709437.98 |
| Z71 | PERSONS ENCNTR HEALTH SERV FOR OTH CNSL AND MED ADVICE, NEC | 296 | 5262118.04 |
| Z73 | PROBLEMS RELATED TO LIFE MANAGEMENT DIFFICULTY | 57 | 806437.95 |
| Z76 | PERSONS ENCOUNTERING HEALTH SERVICES IN OTHER CIRCUMSTANCES | 276 | 3906083.49 |
| Z78 | OTHER SPECIFIED HEALTH STATUS | 140 | 2383334.34 |
| Z79 | LONG TERM (CURRENT) DRUG THERAPY | 306 | 4140461.81 |
| Z91 | PERSONAL RISK FACTORS, NOT ELSEWHERE CLASSIFIED | 61 | 1180551.74 |
| Z95 | PRESENCE OF CARDIAC AND VASCULAR IMPLANTS AND GRAFTS | 44 | 516860.30 |
| Z96 | PRESENCE OF OTHER FUNCTIONAL IMPLANTS | 223 | 3361357.48 |
| Z97 | PRESENCE OF OTHER DEVICES | 64 | 857394.20 |
| 67705 | 1041621279.95 |
| CCSR1X VALUE | CCSR1X LABEL | CCSR2X VALUE | CCSR2X LABEL | CCSR3X VALUE | CCSR3X LABEL | CCSR4X VALUE | CCSR4X LABEL | UNWEIGHTED | WEIGHTED BY perwt24f |
|---|---|---|---|---|---|---|---|---|---|
| -15 | CANNOT BE COMPUTED | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 380 | 6662455.69 |
| BLD000 | DISEASES OF BLOOD AND DISORDERS INVOLVING IMMUNE MECHANIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 120 | 1863545.78 |
| BLD000 | DISEASES OF BLOOD AND DISORDERS INVOLVING IMMUNE MECHANIS | CIR000 | DISEASES OF THE CIRCULATORY SYSTEM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1 | 9708.32 |
| BLD000 | DISEASES OF BLOOD AND DISORDERS INVOLVING IMMUNE MECHANIS | INJ000 | INJURY, POISONING & CERTAIN OTH CONSEQUENCES OF EXTNL CAU | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1 | 4341.71 |
| BLD000 | DISEASES OF BLOOD AND DISORDERS INVOLVING IMMUNE MECHANIS | NEO000 | NEOPLASMS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 6 | 87931.50 |
| BLD001 | NUTRITIONAL ANEMIA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 66 | 917397.63 |
| BLD003 | APLASTIC ANEMIA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 107 | 1452015.72 |
| BLD006 | COAGULATION AND HEMORRHAGIC DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 40 | 702159.83 |
| CIR000 | DISEASES OF THE CIRCULATORY SYSTEM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 395 | 5336268.09 |
| CIR000 | DISEASES OF THE CIRCULATORY SYSTEM | FAC000 | FACTORS INFLUENCING HEALTH STATUS & CONTACT W/ HEALTH SER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 80 | 1057916.69 |
| CIR000 | DISEASES OF THE CIRCULATORY SYSTEM | MUS000 | DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 3 | 74500.42 |
| CIR004 | ENDOCARDITIS AND ENDOCARDIAL DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 108 | 1513476.51 |
| CIR007 | ESSENTIAL HYPERTENSION | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 4357 | 61741124.31 |
| CIR009 | ACUTE MYOCARDIAL INFARCTION | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 288 | 3972551.36 |
| CIR011 | CORONARY ATHEROSCLEROSIS AND OTHER HEART DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 537 | 7340281.63 |
| CIR011 | CORONARY ATHEROSCLEROSIS AND OTHER HEART DISEASE | FAC009 | IMPLANT, DEVICE OR GRAFT RELATED ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 44 | 516860.30 |
| CIR012 | NONSPECIFIC CHEST PAIN | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 143 | 2026408.90 |
| CIR013 | ACUTE PULMONARY EMBOLISM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 57 | 938711.49 |
| CIR015 | OTHER AND ILL-DEFINED HEART DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 161 | 2295297.21 |
| CIR017 | CARDIAC DYSRHYTHMIAS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 597 | 8018943.95 |
| CIR019 | HEART FAILURE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 146 | 1830758.68 |
| CIR020 | CEREBRAL INFARCTION | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 42 | 504629.00 |
| CIR026 | PERIPHERAL AND VISCERAL VASCULAR DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 42 | 586778.62 |
| CIR030 | AORTIC AND PERIPHERAL ARTERIAL EMBOLISM OR THROMBOSIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 228 | 3040509.53 |
| CIR031 | HYPOTENSION | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 57 | 662006.31 |
| CIR032 | OTHER SPECIFIED AND UNSPECIFIED CIRCULATORY DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 54 | 630483.31 |
| CIR035 | VARICOSE VEINS OF LOWER EXTREMITY | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 43 | 602339.75 |
| CIR039 | OTHER SPECIFIED DISEASES OF VEINS AND LYMPHATICS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 47 | 674864.17 |
| DEN000 | DENTAL DISEASES | DIG000 | DISEASES OF THE DIGESTIVE SYSTEM | INF000 | CERTAIN INFECTIOUS AND PARASITIC DISEASES | -1 | INAPPLICABLE | 46 | 755127.14 |
| DEN000 | DENTAL DISEASES | DIG000 | DISEASES OF THE DIGESTIVE SYSTEM | MUS000 | DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TIS | -1 | INAPPLICABLE | 3 | 100472.52 |
| DEN000 | DENTAL DISEASES | FAC000 | FACTORS INFLUENCING HEALTH STATUS & CONTACT W/ HEALTH SER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 18 | 256479.23 |
| DEN000 | DENTAL DISEASES | INJ000 | INJURY, POISONING & CERTAIN OTH CONSEQUENCES OF EXTNL CAU | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 22 | 379924.37 |
| DEN000 | DENTAL DISEASES | MUS000 | DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 33 | 482973.42 |
| DEN001 | ANY DENTAL CONDITION INCLUDING TRAUMATIC INJURY | DEN002 | NONTRAUMATIC DENTAL CONDITIONS | DEN003 | CARIES, PERIODONTITIS, AND OTHER PREVENTABLE DENTAL CONDS | DIG002 | DISORDERS OF TEETH AND GINGIVA | 273 | 4747808.91 |
| DEN001 | ANY DENTAL CONDITION INCLUDING TRAUMATIC INJURY | DEN002 | NONTRAUMATIC DENTAL CONDITIONS | DIG002 | DISORDERS OF TEETH AND GINGIVA | -1 | INAPPLICABLE | 103 | 1845236.11 |
| DEN001 | ANY DENTAL CONDITION INCLUDING TRAUMATIC INJURY | DEN002 | NONTRAUMATIC DENTAL CONDITIONS | DIG003 | DISEASES OF MOUTH; EXCLUDING DENTAL | -1 | INAPPLICABLE | 45 | 794474.46 |
| DEN001 | ANY DENTAL CONDITION INCLUDING TRAUMATIC INJURY | INJ048 | OPEN WOUNDS OF HEAD AND NECK, SUBSEQUENT ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 43 | 675279.93 |
| DIG000 | DISEASES OF THE DIGESTIVE SYSTEM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 284 | 4831948.91 |
| DIG000 | DISEASES OF THE DIGESTIVE SYSTEM | INF000 | CERTAIN INFECTIOUS AND PARASITIC DISEASES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 69 | 981310.49 |
| DIG001 | INTESTINAL INFECTION | INF008 | VIRAL INFECTION | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 116 | 2302559.66 |
| DIG004 | ESOPHAGEAL DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1314 | 19282133.45 |
| DIG005 | GASTRODUODENAL ULCER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 63 | 983946.85 |
| DIG007 | GASTRITIS AND DUODENITIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 90 | 1136438.72 |
| DIG008 | OTH SPECIFIED & UNSPECIFIED DISORDERS OF STOMACH & DUODEN | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 234 | 3360805.21 |
| DIG010 | ABDOMINAL HERNIA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 144 | 1959970.11 |
| DIG011 | REGIONAL ENTERITIS AND ULCERATIVE COLITIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 68 | 1234924.02 |
| DIG013 | DIVERTICULOSIS AND DIVERTICULITIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 77 | 1023506.66 |
| DIG014 | HEMORRHOIDS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 50 | 755648.26 |
| DIG017 | BILIARY TRACT DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 63 | 1016646.49 |
| DIG019 | OTHER SPECIFIED AND UNSPECIFIED LIVER DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 115 | 1839540.48 |
| DIG022 | NONINFECTIOUS GASTROENTERITIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 59 | 912257.27 |
| DIG025 | OTHER SPECIFIED AND UNSPECIFIED GASTROINTESTINAL DISORDER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 429 | 6641458.94 |
| EAR000 | DISEASES OF THE EAR AND MASTOID PROCESS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 107 | 1815431.68 |
| EAR001 | OTITIS MEDIA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 396 | 8017189.91 |
| EAR004 | HEARING LOSS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 284 | 4272524.60 |
| EAR006 | OTHER SPECIFIED AND UNSPECIFIED DISORDERS OF THE EAR | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 240 | 3835085.31 |
| END000 | ENDOCRINE, NUTRITIONAL AND METABOLIC DISEASES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 109 | 1815830.48 |
| END000 | ENDOCRINE, NUTRITIONAL AND METABOLIC DISEASES | EYE000 | DISEASES OF THE EYE AND ADNEXA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 39 | 541329.76 |
| END000 | ENDOCRINE, NUTRITIONAL AND METABOLIC DISEASES | GEN000 | DISEASES OF THE GENITOURINARY SYSTEM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 14 | 202285.35 |
| END000 | ENDOCRINE, NUTRITIONAL AND METABOLIC DISEASES | SKN000 | DISEASES OF THE SKIN AND SUBCUTANEOUS TISSUE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 9 | 112050.50 |
| END001 | THYROID DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1473 | 21987112.19 |
| END002 | DIABETES MELLITUS WITHOUT COMPLICATION | END005 | DIABETES MELLITUS, TYPE 2 | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 2026 | 28984205.07 |
| END003 | DIABETES MELLITUS WITH COMPLICATION | END005 | DIABETES MELLITUS, TYPE 2 | NVS020 | OTH NERV SYS DISORDERS (NEITHER HEREDITARY OR DEGENERATIV | -1 | INAPPLICABLE | 50 | 579144.54 |
| END007 | NUTRITIONAL DEFICIENCIES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 643 | 9798366.82 |
| END009 | OBESITY | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 129 | 2245613.33 |
| END010 | DISORDERS OF LIPID METABOLISM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 3667 | 51513465.51 |
| END011 | FLUID AND ELECTROLYTE DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 315 | 3983941.78 |
| END015 | OTHER SPECIFIED AND UNSPECIFIED ENDOCRINE DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 278 | 4900018.05 |
| END016 | OTH SPECIFIED & UNSPEC NUTRITIONAL AND METABOLIC DISORDER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 198 | 3184468.30 |
| EXT000 | EXTERNAL CAUSES OF MORBIDITY | INJ000 | INJURY, POISONING & CERTAIN OTH CONSEQUENCES OF EXTNL CAU | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 29 | 511229.76 |
| EXT000 | EXTERNAL CAUSES OF MORBIDITY | INJ000 | INJURY, POISONING & CERTAIN OTH CONSEQUENCES OF EXTNL CAU | MBD000 | MENTAL, BEHAVIORAL AND NEURODEVELOPMEN TAL DISORDERS | -1 | INAPPLICABLE | 1 | 43824.72 |
| EYE000 | DISEASES OF THE EYE AND ADNEXA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 126 | 2018669.77 |
| EYE000 | DISEASES OF THE EYE AND ADNEXA | INF000 | CERTAIN INFECTIOUS AND PARASITIC DISEASES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1 | 7826.38 |
| EYE000 | DISEASES OF THE EYE AND ADNEXA | INJ000 | INJURY, POISONING & CERTAIN OTH CONSEQUENCES OF EXTNL CAU | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1 | 23463.55 |
| EYE001 | CORNEA AND EXTERNAL DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 222 | 3950464.32 |
| EYE002 | CATARACT AND OTHER LENS DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 572 | 7279278.82 |
| EYE003 | GLAUCOMA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 345 | 4723195.20 |
| EYE004 | UVEITIS AND OCULAR INFLAMMATION | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 58 | 902087.06 |
| EYE005 | RETINAL AND VITREOUS CONDITIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 350 | 4604432.63 |
| EYE008 | OCULOFACIAL PLASTICS AND ORBITAL CONDITIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 270 | 3667103.73 |
| EYE009 | REFRACTIVE ERROR | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 295 | 5785183.58 |
| EYE010 | BLINDNESS AND VISION DEFECTS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 255 | 4077697.76 |
| EYE012 | OTHER SPECIFIED EYE DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 190 | 2824265.87 |
| FAC000 | FACTORS INFLUENCING HEALTH STATUS & CONTACT W/ HEALTH SER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 292 | 5372970.17 |
| FAC003 | ENCTR FOR OBS, EXAM COND R/O, EXCL INFECT DIS, NPL, MENT | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 236 | 3512645.80 |
| FAC005 | ENCOUNTER FOR PROPHYLACTIC MEASURES (EXCLUDES IMMUNIZATIO | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 129 | 1708428.95 |
| FAC008 | NEOPLASM-RELATED ENCOUNTERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 274 | 4000157.05 |
| FAC009 | IMPLANT, DEVICE OR GRAFT RELATED ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 332 | 4865130.09 |
| FAC010 | OTHER AFTERCARE ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 161 | 2237348.39 |
| FAC012 | OTHER SPECIFIED ENCOUNTERS AND COUNSELING | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 572 | 9168201.53 |
| FAC013 | CONTRACEPTIVE AND PROCREATIVE MANAGEMENT | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 269 | 6030842.30 |
| FAC014 | MEDICAL EXAMINATION/EVALUATION | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 454 | 7494368.81 |
| FAC016 | EXPOSURE, ENCTR, SCREENING OR CONTACT W/INFECTIOUS DISEA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 387 | 6348720.49 |
| FAC019 | SOCIOECONOMIC/PSYCHOSOCIAL FACTORS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 85 | 1709437.98 |
| FAC020 | LIFESTYLE/LIFE MANAGEMENT FACTORS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 57 | 806437.95 |
| FAC022 | ACQUIRED ABSENCE OF LIMB OR ORGAN | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 56 | 782840.67 |
| FAC025 | OTHER SPECIFIED STATUS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 556 | 8338622.70 |
| GEN000 | DISEASES OF THE GENITOURINARY SYSTEM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 447 | 7537806.81 |
| GEN000 | DISEASES OF THE GENITOURINARY SYSTEM | INF000 | CERTAIN INFECTIOUS AND PARASITIC DISEASES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 7 | 125370.94 |
| GEN002 | ACUTE AND UNSPECIFIED RENAL FAILURE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 66 | 816288.33 |
| GEN004 | URINARY TRACT INFECTIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 575 | 8825390.32 |
| GEN005 | CALCULUS OF URINARY TRACT | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 157 | 2398252.20 |
| GEN006 | OTH SPECIFIED AND UNSPECIFIED DISEASES OF KIDNEY AND URET | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 214 | 2849609.30 |
| GEN007 | OTH SPECIFIED & UNSPECIFIED DISEASES OF BLADDER AND URETH | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 151 | 1905604.43 |
| GEN008 | URINARY INCONTINENCE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 132 | 1659586.90 |
| GEN012 | HYPERPLASIA OF PROSTATE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 316 | 4432945.97 |
| GEN014 | ERECTILE DYSFUNCTION | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 83 | 1325085.15 |
| GEN016 | OTHER SPECIFIED MALE GENITAL DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 94 | 1351309.68 |
| GEN017 | NONMALIGNANT BREAST CONDITIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 137 | 2481721.49 |
| GEN018 | INFLAMMATORY DISEASES OF FEMALE PELVIC ORGANS | GEN025 | OTHER SPECIFIED FEMALE GENITAL DISORDERS | INF004 | FUNGAL INFECTIONS | -1 | INAPPLICABLE | 53 | 973858.56 |
| GEN020 | PROLAPSE OF FEMALE GENITAL ORGANS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 66 | 1041855.68 |
| GEN021 | MENSTRUAL DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 79 | 1826087.18 |
| GEN022 | BENIGN OVARIAN CYST | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 46 | 785506.29 |
| GEN025 | OTHER SPECIFIED FEMALE GENITAL DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 125 | 2043873.98 |
| INF000 | CERTAIN INFECTIOUS AND PARASITIC DISEASES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 253 | 4006552.86 |
| INF000 | CERTAIN INFECTIOUS AND PARASITIC DISEASES | MUS000 | DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 5 | 49265.66 |
| INF000 | CERTAIN INFECTIOUS AND PARASITIC DISEASES | NVS000 | DISEASES OF THE NERVOUS SYSTEM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1 | 12709.05 |
| INF000 | CERTAIN INFECTIOUS AND PARASITIC DISEASES | RSP000 | DISEASES OF THE RESPIRATORY SYSTEM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 9 | 110556.50 |
| INF000 | CERTAIN INFECTIOUS AND PARASITIC DISEASES | SKN000 | DISEASES OF THE SKIN AND SUBCUTANEOUS TISSUE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 3 | 67364.41 |
| INF003 | BACTERIAL INFECTIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 85 | 1388127.46 |
| INF003 | BACTERIAL INFECTIONS | RSP006 | OTHER SPECIFIED UPPER RESPIRATORY INFECTIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 312 | 6199730.74 |
| INF004 | FUNGAL INFECTIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 135 | 2032911.40 |
| INF006 | HIV INFECTION | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 41 | 519624.86 |
| INF008 | VIRAL INFECTION | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 244 | 4502467.33 |
| INF008 | VIRAL INFECTION | SKN007 | OTHER SPECIFIED AND UNSPECIFIED SKIN DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 80 | 1437910.43 |
| INF009 | PARASITIC, OTHER SPECIFIED AND UNSPECIFIED INFECTIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 55 | 706700.84 |
| INF012 | CORONAVIRUS DISEASE - 2019 (COVID-19) | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 637 | 10056822.85 |
| INJ000 | INJURY, POISONING & CERTAIN OTH CONSEQUENCES OF EXTNL CAU | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 419 | 6791716.55 |
| INJ000 | INJURY, POISONING & CERTAIN OTH CONSEQUENCES OF EXTNL CAU | MBD000 | MENTAL, BEHAVIORAL AND NEURODEVELOPMEN TAL DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 7 | 133065.56 |
| INJ000 | INJURY, POISONING & CERTAIN OTH CONSEQUENCES OF EXTNL CAU | NVS000 | DISEASES OF THE NERVOUS SYSTEM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 4 | 47788.82 |
| INJ000 | INJURY, POISONING & CERTAIN OTH CONSEQUENCES OF EXTNL CAU | PRG000 | PREGNANCY, CHILDBIRTH AND THE PUERPERIUM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1 | 20060.22 |
| INJ000 | INJURY, POISONING & CERTAIN OTH CONSEQUENCES OF EXTNL CAU | SKN000 | DISEASES OF THE SKIN AND SUBCUTANEOUS TISSUE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 47 | 776785.04 |
| INJ031 | ALLERGIC REACTIONS | RSP007 | OTHER SPECIFIED AND UNSPECIFIED UPPER RESPIRATORY DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 918 | 13729624.20 |
| INJ031 | ALLERGIC REACTIONS | SKN005 | CONTACT DERMATITIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 97 | 1791850.62 |
| INJ031 | ALLERGIC REACTIONS | SKN007 | OTHER SPECIFIED AND UNSPECIFIED SKIN DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 225 | 4018332.26 |
| INJ039 | FRACTURE OF THE SPINE AND BACK, SUBSEQUENT ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 40 | 551635.67 |
| INJ041 | FRACTURE OF THE UPPER LIMB, SUBSEQUENT ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 144 | 2406738.96 |
| INJ042 | FRACTURE OF LOWER LIMB (EXCEPT HIP), SUBSEQUENT ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 149 | 2371144.91 |
| INJ045 | TRAUMATIC BRAIN INJURY (TBI); CONCUSSION, SUBSEQUENT ENCT | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 73 | 1148919.68 |
| INJ049 | OPEN WOUNDS TO LIMBS, SUBSEQUENT ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 56 | 822743.14 |
| INJ060 | TOXIC EFFECTS, SUBSEQUENT ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 71 | 1138603.22 |
| INJ061 | SPRAINS AND STRAINS, SUBSEQUENT ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 364 | 6067612.72 |
| INJ064 | OTHER UNSPECIFIED INJURIES, SUBSEQUENT ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 858 | 13771110.91 |
| INJ067 | ALLERGIC REACTIONS, SUBSEQUENT ENCOUNTER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 297 | 4963077.41 |
| INJ072 | COMPLC OF OTHER SURGICAL/MEDICAL CARE, INJURY, SUBSEQ ENC | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 45 | 709473.29 |
| MAL000 | CONGENITAL MALFORMATIONS, DEFORMATIONS & CHROMOSOMAL ABNO | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 115 | 2308745.44 |
| MBD000 | MENTAL, BEHAVIORAL AND NEURODEVELOPMEN TAL DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 321 | 5849305.02 |
| MBD000 | MENTAL, BEHAVIORAL AND NEURODEVELOPMEN TAL DISORDERS | PRG000 | PREGNANCY, CHILDBIRTH AND THE PUERPERIUM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 22 | 468962.00 |
| MBD001 | SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 47 | 584602.53 |
| MBD002 | DEPRESSIVE DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1649 | 27393709.13 |
| MBD003 | BIPOLAR AND RELATED DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 203 | 3265301.02 |
| MBD004 | OTHER SPECIFIED AND UNSPECIFIED MOOD DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 89 | 1420070.16 |
| MBD005 | ANXIETY AND FEAR-RELATED DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1957 | 34186403.14 |
| MBD006 | OBSESSIVE -COMPULSIVE AND RELATED DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 59 | 1155530.54 |
| MBD007 | TRAUMA- AND STRESSOR-RELATED DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 396 | 6973866.38 |
| MBD013 | MISCELLANEOUS MENTAL AND BEHAVIORAL DISORDERS /CONDITIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 348 | 6492536.35 |
| MBD014 | NEURODEVELOPMEN TAL DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 887 | 17629619.99 |
| MUS000 | DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 344 | 5474818.72 |
| MUS000 | DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TIS | SKN000 | DISEASES OF THE SKIN AND SUBCUTANEOUS TISSUE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 29 | 561827.61 |
| MUS003 | RHEUMATOID ARTHRITIS AND RELATED DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 321 | 3939556.01 |
| MUS006 | OSTEOARTHRITIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1313 | 17924529.73 |
| MUS007 | OTHER SPECIFIED JOINT DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 210 | 3008700.47 |
| MUS009 | TENDON AND SYNOVIAL DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 288 | 4288191.13 |
| MUS010 | MUSCULOSKELETAL PAIN, NOT LOW BACK PAIN | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 2685 | 40943271.84 |
| MUS011 | SPONDYLOPATHIES/SPONDYLOARTHROP ATHY (INCLUDING INFECTIVE) | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 659 | 9514683.82 |
| MUS011 | SPONDYLOPATHIES/SPONDYLOARTHROP ATHY (INCLUDING INFECTIVE) | MUS038 | LOW BACK PAIN | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 417 | 6097939.41 |
| MUS013 | OSTEOPOROSIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 222 | 2881356.14 |
| MUS021 | ACQUIRED FOOT DEFORMITIES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 65 | 960293.98 |
| MUS022 | SCOLIOSIS AND OTHER POSTURAL DORSOPATHIC DEFORMITIES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 67 | 1097303.62 |
| MUS024 | SYSTEMIC LUPUS ERYTHEMATOSUS AND CONNECTIVE TISSUE DISORD | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 113 | 1767179.04 |
| MUS025 | OTHER SPECIFIED CONNECTIVE TISSUE DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 587 | 8456775.11 |
| MUS026 | MUSCLE DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 130 | 1991566.30 |
| MUS028 | OTHER SPECIFIED BONE DISEASE AND MUSCULOSKELETAL DEFORMIT | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 279 | 4020113.69 |
| MUS033 | GOUT | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 262 | 3539487.47 |
| MUS038 | LOW BACK PAIN | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 379 | 5746609.75 |
| NEO000 | NEOPLASMS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 355 | 5261561.05 |
| NEO000 | NEOPLASMS | NVS000 | DISEASES OF THE NERVOUS SYSTEM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 2 | 27820.27 |
| NEO022 | RESPIRATORY CANCERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 45 | 569597.04 |
| NEO025 | SKIN CANCERS - MELANOMA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 149 | 2094294.08 |
| NEO026 | SKIN CANCERS - BASAL CELL CARCINOMA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 99 | 1356066.42 |
| NEO027 | SKIN CANCERS - SQUAMOUS CELL CARCINOMA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 53 | 814946.16 |
| NEO028 | SKIN CANCERS - ALL OTHER TYPES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 429 | 6301098.64 |
| NEO030 | BREAST CANCER - ALL OTHER TYPES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 196 | 2719565.53 |
| NEO039 | MALE REPRODUCTIVE SYSTEM CANCERS - PROSTATE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 182 | 2465915.58 |
| NEO050 | ENDOCRINE SYSTEM CANCERS - THYROID | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 55 | 819515.92 |
| NEO064 | LEUKEMIA - ALL OTHER TYPES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 40 | 487067.31 |
| NEO072 | NEOPLASMS OF UNSPECIFIED NATURE OR UNCERTAIN BEHAVIOR | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 163 | 2161083.08 |
| NEO073 | BENIGN NEOPLASMS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 282 | 4567344.73 |
| NVS000 | DISEASES OF THE NERVOUS SYSTEM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 187 | 2875465.04 |
| NVS000 | DISEASES OF THE NERVOUS SYSTEM | SYM000 | SYMPTOMS, SIGNS AND ABNORMAL CLINICAL & LAB FINDINGS, NEC | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1 | 16076.24 |
| NVS004 | PARKINSON`S DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 62 | 637710.82 |
| NVS005 | MULTIPLE SCLEROSIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 50 | 839734.36 |
| NVS006 | OTHER NERV SYS DISORDERS (OFTEN HEREDITARY OR DEGENERATIV | NVS016 | SLEEP WAKE DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 124 | 1756518.33 |
| NVS009 | EPILEPSY; CONVULSIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 175 | 2555220.91 |
| NVS010 | HEADACHE; INCLUDING MIGRAINE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 389 | 6538388.37 |
| NVS010 | HEADACHE; INCLUDING MIGRAINE | SYM010 | NERVOUS SYSTEM SIGNS AND SYMPTOMS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 147 | 2250137.19 |
| NVS011 | NEUROCOGNITIVE DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 79 | 1016387.89 |
| NVS012 | TRANSIENT CEREBRAL ISCHEMIA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 230 | 3029377.18 |
| NVS015 | POLYNEUROPATHIES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 282 | 3809475.57 |
| NVS016 | SLEEP WAKE DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1201 | 18206528.65 |
| NVS017 | NERVE AND NERVE ROOT DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 246 | 3397128.41 |
| NVS019 | NERVOUS SYSTEM PAIN AND PAIN SYNDROMES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 301 | 4693906.89 |
| NVS020 | OTH NERV SYS DISORDERS (NEITHER HEREDITARY OR DEGENERATIV | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 55 | 941960.67 |
| PNL000 | CERTAIN CONDITIONS ORIGINATING IN THE PERINATAL PERIOD | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 13 | 212354.67 |
| PNL001 | LIVEBORN | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 42 | 963325.80 |
| PRG000 | PREGNANCY, CHILDBIRTH AND THE PUERPERIUM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 116 | 2287866.75 |
| PRG029 | UNCOMPLICATED PREGNANCY, DELIVERY OR PUERPERIUM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 190 | 3900588.71 |
| RSP000 | DISEASES OF THE RESPIRATORY SYSTEM | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 119 | 1986248.26 |
| RSP001 | SINUSITIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 428 | 7105378.59 |
| RSP002 | PNEUMONIA (EXCEPT THAT CAUSED BY TUBERCULOSIS) | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 275 | 4299767.53 |
| RSP003 | INFLUENZA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 274 | 5071178.96 |
| RSP004 | ACUTE AND CHRONIC TONSILLITIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 52 | 1014250.32 |
| RSP005 | ACUTE BRONCHITIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 206 | 3511497.38 |
| RSP006 | OTHER SPECIFIED UPPER RESPIRATORY INFECTIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 458 | 8330133.15 |
| RSP007 | OTHER SPECIFIED AND UNSPECIFIED UPPER RESPIRATORY DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 223 | 3597137.63 |
| RSP008 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND BRONCHIECTASIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 380 | 4744758.84 |
| RSP009 | ASTHMA | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1247 | 19410818.09 |
| RSP016 | OTHER SPECIFIED AND UNSPECIFIED LOWER RESPIRATORY DISEASE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 195 | 3388232.21 |
| SKN000 | DISEASES OF THE SKIN AND SUBCUTANEOUS TISSUE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 73 | 1338672.43 |
| SKN001 | SKIN AND SUBCUTANEOUS TISSUE INFECTIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 262 | 4438965.44 |
| SKN002 | OTHER SPECIFIED INFLAMMATORY CONDITION OF SKIN | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 494 | 8672619.87 |
| SKN007 | OTHER SPECIFIED AND UNSPECIFIED SKIN DISORDERS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 1030 | 16107081.15 |
| SYM000 | SYMPTOMS, SIGNS AND ABNORMAL CLINICAL & LAB FINDINGS, NEC | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 282 | 4723315.57 |
| SYM002 | FEVER | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 100 | 1847284.05 |
| SYM004 | NAUSEA AND VOMITING | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 285 | 4652634.65 |
| SYM006 | ABDOMINAL PAIN & OTHER DIGESTIVE/ABDOMEN SIGNS AND SYMPTO | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 549 | 8214568.62 |
| SYM007 | MALAISE AND FATIGUE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 77 | 1055280.23 |
| SYM008 | SYMPTOMS OF MENTAL AND SUBSTANCE USE CONDITIONS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 57 | 894612.00 |
| SYM010 | NERVOUS SYSTEM SIGNS AND SYMPTOMS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 375 | 5323283.32 |
| SYM011 | GENITOURINARY SIGNS AND SYMPTOMS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 158 | 2236632.41 |
| SYM012 | CIRCULATORY SIGNS AND SYMPTOMS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 308 | 4265160.86 |
| SYM013 | RESPIRATORY SIGNS AND SYMPTOMS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 599 | 8859727.00 |
| SYM014 | SKIN /SUBCUTANEOUS SIGNS AND SYMPTOMS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 362 | 5740557.10 |
| SYM015 | GENERAL SENSATION/PERCEPTION SIGNS AND SYMPTOMS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 229 | 2994045.36 |
| SYM016 | OTHER GENERAL SIGNS AND SYMPTOMS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 764 | 10952550.36 |
| SYM017 | ABNORMAL FINDINGS WITHOUT DIAGNOSIS | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 306 | 4584335.13 |
| SYM018 | PREDIABETES | -1 | INAPPLICABLE | -1 | INAPPLICABLE | -1 | INAPPLICABLE | 249 | 4064411.59 |
| 67705 | 1041621279.95 |
|
|||||
Back
Email Updates
